453 related articles for article (PubMed ID: 26313344)
1. A challenge for theranostics: is the optimal particle for therapy also optimal for diagnostics?
Dreifuss T; Betzer O; Shilo M; Popovtzer A; Motiei M; Popovtzer R
Nanoscale; 2015 Oct; 7(37):15175-84. PubMed ID: 26313344
[TBL] [Abstract][Full Text] [Related]
2. pH-responsive unimolecular micelle-gold nanoparticles-drug nanohybrid system for cancer theranostics.
Lin W; Yao N; Qian L; Zhang X; Chen Q; Wang J; Zhang L
Acta Biomater; 2017 Aug; 58():455-465. PubMed ID: 28583900
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model.
Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin MH; Wang HE
Bioorg Med Chem Lett; 2013 Jun; 23(11):3180-5. PubMed ID: 23628334
[TBL] [Abstract][Full Text] [Related]
4. Chemistry for oncotheranostic gold nanoparticles.
Trouiller AJ; Hebié S; El Bahhaj F; Napporn TW; Bertrand P
Eur J Med Chem; 2015 Jun; 99():92-112. PubMed ID: 26057706
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer.
Davidi ES; Dreifuss T; Motiei M; Shai E; Bragilovski D; Lubimov L; Kindler MJJ; Popovtzer A; Don J; Popovtzer R
Head Neck; 2018 Jan; 40(1):70-78. PubMed ID: 29130566
[TBL] [Abstract][Full Text] [Related]
6. Gold Nanoparticles as Targeted Delivery Systems and Theranostic Agents in Cancer Therapy.
Mioc A; Mioc M; Ghiulai R; Voicu M; Racoviceanu R; Trandafirescu C; Dehelean C; Coricovac D; Soica C
Curr Med Chem; 2019; 26(35):6493-6513. PubMed ID: 31057102
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Membrane Antigen Targeted Gold Nanoparticles for Theranostics of Prostate Cancer.
Mangadlao JD; Wang X; McCleese C; Escamilla M; Ramamurthy G; Wang Z; Govande M; Basilion JP; Burda C
ACS Nano; 2018 Apr; 12(4):3714-3725. PubMed ID: 29641905
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of gold-DTDTPA nanoparticles as theranostic agents in prostate cancer radiotherapy.
Butterworth KT; Nicol JR; Ghita M; Rosa S; Chaudhary P; McGarry CK; McCarthy HO; Jimenez-Sanchez G; Bazzi R; Roux S; Tillement O; Coulter JA; Prise KM
Nanomedicine (Lond); 2016 Aug; 11(16):2035-47. PubMed ID: 27463088
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional gold-based nanocomposites for theranostics.
Dykman LA; Khlebtsov NG
Biomaterials; 2016 Nov; 108():13-34. PubMed ID: 27614818
[TBL] [Abstract][Full Text] [Related]
10. Thermo-responsive Fluorescent Nanoparticles for Multimodal Imaging and Treatment of Cancers.
Pandey N; Menon JU; Takahashi M; Hsieh JT; Yang J; Nguyen KT; Wadajkar AS
Nanotheranostics; 2020; 4(1):1-13. PubMed ID: 31911890
[TBL] [Abstract][Full Text] [Related]
11. Lanthanide (Gd(3+) and Yb(3+)) functionalized gold nanoparticles for in vivo imaging and therapy.
Ge X; Song ZM; Sun L; Yang YF; Shi L; Si R; Ren W; Qiu X; Wang H
Biomaterials; 2016 Nov; 108():35-43. PubMed ID: 27619238
[TBL] [Abstract][Full Text] [Related]
12. In-vitro Optimization of Nanoparticle-Cell Labeling Protocols for In-vivo Cell Tracking Applications.
Betzer O; Meir R; Dreifuss T; Shamalov K; Motiei M; Shwartz A; Baranes K; Cohen CJ; Shraga-Heled N; Ofir R; Yadid G; Popovtzer R
Sci Rep; 2015 Oct; 5():15400. PubMed ID: 26507853
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cellular uptake and phototoxicity of Verteporfin-conjugated gold nanoparticles as theranostic nanocarriers for targeted photodynamic therapy and imaging of cancers.
Zhao L; Kim TH; Kim HW; Ahn JC; Kim SY
Mater Sci Eng C Mater Biol Appl; 2016 Oct; 67():611-622. PubMed ID: 27287160
[TBL] [Abstract][Full Text] [Related]
14. Hybrid graphene/Au activatable theranostic agent for multimodalities imaging guided enhanced photothermal therapy.
Gao S; Zhang L; Wang G; Yang K; Chen M; Tian R; Ma Q; Zhu L
Biomaterials; 2016 Feb; 79():36-45. PubMed ID: 26691399
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules.
Vigderman L; Zubarev ER
Adv Drug Deliv Rev; 2013 May; 65(5):663-76. PubMed ID: 22613038
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine for Cancer Immunotherapy: Tracking Cancer-Specific T-Cells in Vivo with Gold Nanoparticles and CT Imaging.
Meir R; Shamalov K; Betzer O; Motiei M; Horovitz-Fried M; Yehuda R; Popovtzer A; Popovtzer R; Cohen CJ
ACS Nano; 2015 Jun; 9(6):6363-72. PubMed ID: 26039633
[TBL] [Abstract][Full Text] [Related]
17. Metal nanoparticles: a theranostic nanotool against cancer.
Sharma H; Mishra PK; Talegaonkar S; Vaidya B
Drug Discov Today; 2015 Sep; 20(9):1143-51. PubMed ID: 26007605
[TBL] [Abstract][Full Text] [Related]
18. Fattigation-platform theranostic nanoparticles for cancer therapy.
Tran TT; Tran PH; Yoon TJ; Lee BJ
Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():1161-1167. PubMed ID: 28415402
[TBL] [Abstract][Full Text] [Related]
19. Taxane-Grafted Metal-Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel-Functionalized Titanate Nanotubes on Prostate Tumors.
Loiseau A; Boudon J; Mirjolet C; Créhange G; Millot N
Adv Healthc Mater; 2017 Aug; 6(16):. PubMed ID: 28516460
[TBL] [Abstract][Full Text] [Related]
20. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma.
Wang Y; Sui G; Teng D; Wang Q; Qu J; Zhu L; Ran H; Wang Z; Jin C; Wang H
Biomater Sci; 2018 Dec; 7(1):196-210. PubMed ID: 30422139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
